|
Vaccine Detail
NA-17/MAGE-3.A2/NY-ESO-1 Peptide Vaccine |
Vaccine Information |
- Vaccine Name: NA-17/MAGE-3.A2/NY-ESO-1 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007092
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- MAGEA3
gene engineering:
- CTAG1B
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Melanoma Cancer (NCT01308294). It is a peptide cancer vaccine consisting of peptides derived from the melanoma antigen NA-17, the human leukocyte antigen HLA-A2-restricted human melanoma antigen 3 (MAGE-3.A2) and the cancer-testis antigen (NY-ESO-1), with potential immunostimulating and antineoplastic activities. Upon administration, the NA-17/MAGE-3.A2/NY-ESO-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing NA-17, MAGE-3.A2 and NY-ESO-1, resulting in tumor cell lysis. The tumor-associated antigens (TAAs) NA-17, MAGE-3.A2 and NY-ESO-1 are overexpressed in a variety of cancer cell types (NCIT_C96042; Miller et al., 2014).
|
Host Response |
|
References |
Miller et al., 2014: Miller MJ, Foy KC, Overholser JP, Nahta R, Kaumaya PT. HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells. Oncoimmunology. 2014; 3(11); e956012. [PubMed: 25941588].
NCIT_C96042: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C96042]
NCT01308294: [https://clinicaltrials.gov/ct2/show/NCT01308294?term=Melan-A%2FMAGE-3.DP4+Peptide+Vaccine&rank=1]
|
|